Ogeda

Biotechnology, Health Care, Health Diagnostics, Pharmaceutical
Founded in 1994-01-01
Brussels, Brussels Hoofdstedelijk Gewest, Belgium
http://www.ogeda.com/
For Profit

About Ogeda

Ogeda (formerly named Euroscreen) is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women's health disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. Ogeda is backed by leading investors, including Vealius Biocapital II SA Sicar, Fund+ NV, SRIW SA, Capricorn Health-Tech Fund NVHT fund, BNP Paribas Fortis Private Equity Management SA. For more information, please visit: www.ogeda.com

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: 9 active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 26000000 EUR
  • Last Funding: 16000000 EUR (Series B)
  • Funding Status: M&A

Technology Stack

Ogeda actively uses 9 products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Health Diagnostics, Pharmaceutical

Headquarters: Brussels, Brussels Hoofdstedelijk Gewest, Belgium